Revise earnings upwards to factor in recovery, upgrade to BUY We revise our earning estimates upwards, 5% and 7.6% for FY17E and FY18E respectively to factor in recovery in demand. We re-rate the business of the company and now value it at 30x FY18E EPS of 52.5 to...